UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

Clinical insights on how the level of PD-L1 expression informs treatment decisions for patients with non–small cell lung cancer.

Experts on non–small cell lung cancer discuss the role of CTLA-4 inhibitors in the NSCLC treatment landscape.

A panel of thoracic medical oncologists provide an overview of first-line treatment strategies for advanced non–small cell lung cancer (NSCLC).

Aaron Lisberg, MD, reviews data from the TROPION-Lung01 study investigating Dato-DXd in previously treated patients with advanced/metastatic NSCLC.

ARX517 displayed preliminary efficacy and a strong safety profile in patients with metastatic castration-resistant prostate cancer, according to findings from the phase 1/2 APEX-01 study.

J. Randolph (Randy) Hecht, MD, discusses barriers to enrollment in the observational BASECAMP-1 study and the phase 1/2 EVEREST-1 study, which will investigate HLA-A*02 as a target for the novel CAR T-cell therapy A2B530 in patients with solid tumors.

J. Randolph (Randy) Hecht, MD, discusses barriers to treatment with CAR T-cell therapy in patients with solid tumors, highlighting various efforts that investigators are spearheading to address these unmet needs.

J. Randolph Hecht, MD, discusses the challenges researchers have faced in the development of cellular therapy for patients with solid tumors, and details how A2B530 could potentially overcome some of these obstacles.

Monica D. Mead, MD, discusses the importance of addressing unanswered questions in the treatment of patients with mantle cell lymphoma.

Rena D. Callahan, MD, discusses the range of metastatic imaging techniques available in breast cancer, the benefits of liquid biopsy, and the importance of looking for bone metastases in patients with metastatic breast cancer.

Monica D. Mead, MD, discusses the efficacy and safety differences between the second-generation BTK inhibitor zanubrutinib and the first-generation BTK inhibitor ibrutinib in patients with mantle cell lymphoma.

Monica D. Mead, MD, discusses reasons for the declining use of the BTK inhibitor ibrutinib in patients with mantle cell lymphoma.

Panelists wrap up their discussion on HER2+ breast cancer by summarizing the most exciting recent advances in the field and their hopes for the future of treatment.

Monica D. Mead, MD, discusses the impact of key data on the role of ibrutinib in the treatment of mantle cell lymphoma.

Monica D. Mead, MD, discusses the evolving use of the BTK inhibitors in the treatment of patients with MCL, the factors for selecting between ibrutinib, zanubrutinib, and acalabrutinib, and unmet needs for patients with MCL.

Dr Kaklamani presents a profile of a patient with HER2+ breast cancer and liver metastases who had disease progression after first-line chemotherapy and a solitary new brain metastasis after second-line T-DM1.

Melinda L. Telli, MD, presents a profile of a patient with early stage breast cancer with residual nodal disease after neoadjuvant chemotherapy and surgery, whose tumor was initially HER2+ but became triple-negative after treatment.

The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.

Virginia G. Kaklamani, MD, DSc, presents a patient profile of early stage HER2+ breast cancer with residual nodal disease after neoadjuvant chemotherapy and surgery.

Experts share their go-to regimens in the third-line and higher setting of HER2+ metastatic breast cancer, and touch on the factors that support their decision-making.

An overview of ongoing research in the endometrial cancer treatment space.

Dana Chase, MD, FACOG, discusses key efficacy, safety, and quality of life data from the RUBY trial supporting the FDA approval of dostarlimab and explains how this approval could help improve the efficacy of current chemotherapy regimens in advanced-stage or recurrent endometrial cancer.

Debu Tripathy, MD, discusses novel therapies being developed for later-line treatment of HER2+ mBC.

The expert panel reviews the KEYNOTE-775 trial, which focused on lenvatinib and pembrolizumab in advanced endometrial cancer.

Drs McArthur and Telli discuss recent data updates from the DESTINY-Breast trials of T-DXd, including a pooled analysis, and share best practices for monitoring patients for lung complications.

A panel of gynecologic oncologists review the PHAEDRA study and discuss the overall treatment landscape for endometrial cancer.

Drs Tripathy and Kaklamani emphasize the most critical unmet needs for patients with HER2+ metastatic breast cancer in the third-line or higher settings and recap what the field previously learned from the HER2CLIMB trial of tucatinib/trastuzumab/capecitabine.

Experts on endometrial cancer review the NRG-GY018 and RUBY clinical trials.

Panelists briefly touch on ongoing trials of second-line tucatinib combination therapy, including HER2CLIMB-02 and HER2CLIMB-05, in patients with or without brain metastases, and offer their clinical perspective which second-line regimens they typically recommend for their patients with HER2+ mBC.

The expert panel switches its focus to endometrial cancer and discusses recent data from clinical trials.